References
- Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–264.
- Abril-Rodriguez G, SnapShot: RA. Immune checkpoint inhibitors. Cancer Cell. 2017;31(6):848–848.e1.
- Chang LS, Barroso-Sousa R, Tolaney SM, et al. Endocrine toxicity of cancer immunotherapy targeting immune checkpoints. Endocr Rev. 2019;40(1):17–65.
- Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. J Clin Oncol. 2018;36(17):1714–1768.
- Matsuoka H, Hayashi T, Takigami K, et al. Correlation between immune-related adverse events and prognosis in patients with various cancers treated with anti PD-1 antibody. BMC Cancer. 2020;20(1):656.
- Paschou SA, Liontos M, Eleftherakis-Papaiakovou E, et al. Oncological patients with endocrine complications after immunotherapy with checkpoint inhibitors present longer progression-free and overall survival. Front Oncol. 2022;12:847917.
- Zagouras A, Patil PD, Yogi-Morren D, et al. Cases from the immune-related adverse event tumor board: diagnosis and management of immune checkpoint blockade-induced diabetes. Oncologist. 2020;25(11):921–924.
- Lu J, Yang J, Liang Y, et al. Incidence of immune checkpoint inhibitor-associated diabetes: a meta-analysis of randomized controlled studies. Front Pharmacol. 2019;10:1453.
- Liu J, Zhou H, Zhang Y, et al. Reporting of immune checkpoint inhibitor therapy-associated diabetes, 2015-2019. Diabetes Care. 2020;43(7):e79–e80.
- Chen X, Affinati AH, Lee Y, et al. Immune checkpoint inhibitors and risk of type 1 diabetes. Diabetes Care. 2022;45(5):1170–1176.
- Wright JJ, Salem JE, Johnson DB, et al. Increased reporting of immune checkpoint inhibitor-associated diabetes. Diabetes Care. 2018;41(12):e150–e151.
- Rui J, Deng S, Arazi A, et al. β cells that resist immunological attack develop during progression of autoimmune diabetes in NOD mice. Cell Metab. 2017;25(3):727–738.
- Youssef N, Noureldein M, Daoud G, et al. Immune checkpoint inhibitors and diabetes: mechanisms and predictors. Diabetes Metab. 2021;47(3):101193.
- Wright JJ, Powers AC, Johnson DB. Endocrine toxicities of immune checkpoint inhibitors. Nat Rev Endocrinol. 2021;17(7):389–399.
- Zheng Z, Liu Y, Yang J, et al. Diabetes mellitus induced by immune checkpoint inhibitors. Diabetes Metab Res Rev. 2021;37(1):e3366.